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Misconceptions of photoprotection in
skin of color
Susan C. Taylor, MD,a Andrew F. Alexis, MD, MPH,b April W. Armstrong, MD, MPH,c
Zelma C. Chiesa Fuxench, MD, MSCE,a and Henry W. Lim, MDd
Philadelphia, Pennsylvania; New York, New York; Los Angeles, California; and Detroit, Michigan
Terrestrial sunlight is the portion of electromagnetic radiation that is emitted by the sun and reaches Earth’s
surface. It encompasses 3 major components: UV radiation (290-400 nm), visible light (400-700 nm), and
infrared radiation. The deleterious effects of UV radiation have been appreciated for decades, particularly
among those with light skin tones (Fitzpatrick skin types I-II) who primarily manifest with burns of varying
degrees of severity with sun exposure. In recent years, studies have increasingly shown the negative impact of
visible light on skin health, particularly in individuals with skin of color (Fitzpatrick skin types IV-VI), including
the exacerbation of hyperpigmentation disorders such as melasma and post-inflammatory hyperpigmentation,
as well as induction of the former. Recommendations from medical societies and the US Food and Drug
Administration for photoprotection have been evolving along with the knowledge base. Yet, misconceptions
about skin damage related to sunlight and the benefits of photoprotection (particularly among those with
Fitzpatrick skin types V-VI) are still prevalent among both clinicians and patients. Among patients with skin of
color, disorders of hyperpigmentation and other consequences from sun exposure have been associated with
impaired skin health and negative burden on quality of life. This review summarizes currently available
evidence of the impact of both UV and visible wavelengths and the low utilization of photoprotection
measures among people with skin of color, with the goal of providing recommendations to help educate
patients. ( J Am Acad Dermatol 2022;86:S9-17.)
Key words: photoprotection; skin of color; sunscreen; ultraviolet light; visible light.

PHOTODAMAGE IN SKIN OF COLOR
It is well documented that exposure to sunlight
induces skin damage and pigment changes, ranging
from sunburn, tanning, and hyperpigmentation to
DNA damage associated with malignancies.1
Research attention has primarily focused on the
negative impact of UV radiation with wavelengths
of 290 to 400 nm.2 However, it is now becoming
increasingly clear that the spectrum of light that can
damage skin encompasses visible light (VL) wavelengths (400-700 nm) as well as UV wavelengths
(Fig 1).3 This may seem somewhat paradoxical,
because dermatologists have successfully employed
VL as therapy for inflammatory and neoplastic
conditions and have typically perceived VL to be
benign compared to other wavelengths.3,4
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Misconception: UV radiation has the most
negative impact on skin for all FSTs
As our understanding of how the different light
wavelengths can damage the skin has grown, our
knowledge about the effects of sunlight on dark skin
types (Fitzpatrick skin types [FSTs] IV-VI) has
advanced. Changes in the skin that occur after
exposure to solar radiation, or photodamage, may
be more readily assessed in individuals with light skin
types (FSTs I-III), but it is now appreciated that all skin
types are susceptible to sunlight-related injury.2 The
Fitzpatrick scale is intended as a gauge of a person’s
ability to burn or tan from solar radiation and not as an
indicator of or proxy for racial, ethnic, or phenotypic
features.5 Nonetheless, because it is a standard that
most dermatologists use to classify skin tone, the FST
Reprints not available from the authors.
Correspondence to: Susan C. Taylor, MD, Department of
Dermatology, Perelman School of Medicine, University of
Pennsylvania, 3400 Civic Center Blvd, South Tower 7-768,
Philadelphia, PA 19104. E-mail: Susan.Taylor@PennMedicine.
upenn.edu.
Published online December 21, 2021.
0190-9622/$36.00
Ó 2021 by the American Academy of Dermatology, Inc.
https://doi.org/10.1016/j.jaad.2021.12.020

S9

J AM ACAD DERMATOL

S10 Taylor et al

MARCH 2022

scale may serve as a foundation for discussions of skin
determinant of cutaneous pigmentation.13 People
of color (SOC). For the purposes of this publication,
with FSTs IV to VI skin have larger, more melanized
people with SOC will be defined as those with FSTs IV
melanosomes, which are distributed individually
to VI. Like those with light skin, individuals with SOC
within the keratinocytes rather than in aggregates
could benefit by incorporating photoprotective mea(Fig 2).2,14 These melanosomes can absorb more UV
sures against sun damage (eg, seeking shade when
energy than those in FSTs I to III. Research has
outdoors, wearing sun-protective clothing, and using
shown that melanin in SOC can filter approximately
protective sunscreen), partic2 to 5 times more UV radiaularly to guard against
tion than melanin in skin of
CAPSULE SUMMARY
pigmentation problems, as
lower FSTs.15,16 Kaidbey
6
will be discussed.
et al17 reported that the
Evidence for the impact of sunlight, both
epidermis of FSTs V to VI
This review summarizes
ultraviolet and visible wavelengths, and
has an intrinsic sun protecinformation on the susceptilow utilization of sunscreen among
tion factor (SPF) of 13.4
bility of individuals with
people with skin of color is summarized.
versus SPF 3.3 in light photoSOC to various forms of
types. In 2014, the American
photodamage,
including
Misconceptions about the importance of
Academy of Dermatology’s
pigmentary disorders and
photoprotection in this population are
recommendations for photomalignancy. This review
highlighted, along with specific
protection in SOC summademonstrates that updated
recommendations to help guide patient
rized research into melanin
education is needed to
education.
biology in individuals with
enhance sun protection
SOC by stating, ‘‘exposure
practices in patients with
to UV radiation plays a lesser role in heightening
SOC; specifically, these patients need to be
the risk for skin cancer’’ due to the photoprotection
informed about the impact of VL on the risk of
provided by increased epidermal melanin.2,17
dyspigmentation, which is associated with a nega7-10
tive impact on quality of life.
Misunderstandings
about appropriate sun protection in people with
Other factors that differ between FSTs
SOC are also discussed, along with the reported use
Although individuals with SOC may have some
of photoprotection in this demographic group, with
level of intrinsic photoprotection, melanin content
the goal of improving patient education.
does not tell the complete story of response to
sunlight in higher FSTs. This is because exposure
to UV radiation can cause DNA damage in all skin
Misconception: the clinical presentation of
types and DNA damage does not appear to be solely
photodamage is consistent across FSTs
related to the degree of pigmentation.18 Oxidative
The manifestations of sun damage in individuals
with SOC (FSTs IV-VI) display both similarities and
stress, sun-induced immunosuppression, and other
differences from those seen in FSTs I to III. People
factors also contribute to the pathophysiology of
with FSTs IV to VI are susceptible to the negative
photodamage in this population.19 A lower risk of
effects of sun exposure. In those with higher FSTs,
DNA damage in FSTs IV to VI from UV radiation is
photodamage is less likely to appear as lines and
also thought to be related to both an increased
wrinkles and more likely to present as pigmentarycapacity to repair DNA and the reduced depth of
related problems, including uneven skin tone, postpenetration of UV radiation compared with light skin
inflammatory hyperpigmentation (PIH), melasma, or
tones.20 In high FSTs, DNA damage after UV expo11
any combination of these characteristics. Evidence
sure occurs mainly in the upper layers of the dermis;
in contrast, DNA damage in low FSTs can occur in all
suggests that these differences may occur because
layers of the skin, including basal layers, and can
FSTs IV to VI offer some degree of protection against
affect stem cells.12
UV-B but is more likely to develop dyspigmentation
12
induced by VL and UV-A1.
Response of SOC to VL
Over the past decade, the role of VL in stimulating
RESPONSE OF SKIN COLOR TO SUNLIGHT
EXPOSURE
erythema, skin pigmentation, thermal damage, and
production of reactive oxygen species (ROS) has
Misconception: endogenous melanin provides
been recognized.21 Lim et al22 present a more comcomplete photoprotection for FSTs IV to VI
Melanin, produced and packaged into melanoplete discussion of the impact of VL in their article,
somes by melanocytes, is transferred into neighImpact of Visible Light on Skin Health: The Role of
boring keratinocytes and serves as an important
Antioxidants and Free Radical Quenchers.
d

d
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Abbreviations used:
cSCC:
FST:
PIH:
ROS:
SOC:
SPF:
VL:

cutaneous squamous cell carcinoma
Fitzpatrick skin type
post-inflammatory hyperpigmentation
reactive oxygen species
skin of color
sun protection factor
visible light

Independently from the effects of UV radiation, VL
exposure induces both transient and long-term
cutaneous pigmentation in a dose-dependent
manner.23 Further, more intense and persistent VLinduced pigmentation occurs in subjects with dark
skin (FSTs V-VI).24 In human skin explants, the
action of VL induces sustained redistribution of
melanin granules from the basal layer of the
epidermis to layers closer to the surface, inducing
melasma and pigmentary problems in SOC.25

CLINICAL PRESENTATIONS OF
PHOTODAMAGE IN SOC
Misconception: disorders characterized by
excess pigmentation on the face and other
body areas only have a cosmetic impact on
patients
Melasma. Melasma is an acquired hypermelanosis, appearing as irregular brown patches, primarily
on sun-exposed areas of the face, neck, and
arms.26,27 Melasma is most common in women,
particularly those of reproductive age and those
with FSTs IV to VI skin. It results after UV radiation
and VL stimulates hyperactivity of melanocytes and
pigment production,27,28 with a subsequent increase
in tyrosine-mediated melanogenesis and increased
transfer of melanosomes to epidermal keratinocytes,
resulting in pigmented patches of skin.28 This may be
exacerbated by estrogen-associated release of
melanocyte-stimulating hormone, explaining why
most melasma cases occur in women.28
The role of light in melasma is further demonstrated by the histopathologic findings of solar
elastosis and ultrastructural alteration of the basement membrane at the dermal-epidermal junction.26
Similar to other pigmentary disorders, melasma is
challenging to manage, with patients often experiencing inconsistent treatment results and a
long-lasting and/or relapsing course, with most
exacerbations occurring during the summer
months.26,29 Melasma has a significant negative
effect on social life and interactions, emotional
well-being, and self-esteem.27 Further, successful
treatment of melasma correlates with a marked
increase in self-esteem; indeed, Jiang et al27
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recommend that ‘‘physicians who treat patients
with melasma should be aware of its profound
€
psychosocial effects.’’ Ozkesici
Kurt et al30 studied
55 patients with melasma and found that internalized
stigma, or the acceptance of negative societal stereotypes, was a primary factor responsible for the
psychological burden of melasma. Although existing
treatments can be effective, they are not curative and
do not impact the relapsing nature of the disease.
Because there are few reliably efficacious treatments
for melasma at the current time, preventative strategies, such as photoprotection, are very important in
managing this condition.31,32
PIH. PIH is another acquired hypermelanosis,
which occurs after cutaneous inflammation.31,33 PIH
can occur in skin types of a light complexion but is
more prevalent in people with SOC (FSTs IV-VI).
Hyperpigmented macules or patches occur at the site
of the original injury or inflammatory insult after
healing, with colors ranging from light brown to
black. Sunlight exposure (both UV and VL) is thought
to exacerbate the condition (Fig 3). Like melasma,
PIH can have a significant negative impact on quality
of life. It is often more bothersome to patients than the
initiating disease or insult, which has been reported in
several diverse acne populations.34 In a study of 324
patients in 7 Asian countries, Abad-Casintahan et al35
observed that PIH lasted longer than 1 year in 65.2%
of patients and 5 years or longer in 22.3%, exacerbating its overall impact on quality of life. In fact, even
mild forms of facial pigmentation can be detrimental
to quality of life, particularly for women.34
Epidemiologic studies have shown that pigmentary
disorders, including PIH and melasma, are among the
most common complaints from patients with high
FSTs who consult dermatologists.33,36-38
Misconception: individuals with SOC have
negligible risks associated with skin cancer
Skin cancers are significantly less prevalent in
persons with SOC relative to those with light skin15,39
and occur in about 5% of Hispanics, 4% of Asians,
and 2% of Blacks.39 However, skin malignancies in
people with SOC are often detected at a more
advanced stage and are associated with a worse
prognosis.40-42
In people with SOC, UV radiation does not appear
to be a major risk factor for melanoma.15 In fact, most
melanomas in SOC patients affect areas not typically
exposed to sunlight, including palmar, plantar, and
subungual skin, as well as mucous membranes, with
acral lentiginous melanoma being the most common
type of melanoma.2 Along with the locations that
differ from people with light skin tones, differentiating normal variants, such as benign melanonychia
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Fig 1. Spectrum of light and impact on skin. R, radiation; VL, visible light.

Fig 2. Differences in skin pigmentation due to melanosome distribution within epidermal
keratinocytes.
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Fig 3. Solar radiation from ultraviolet to visible light triggers pigmentation in melasma and
postinflammatory hyperpigmentation. aMSH, Alpha-melanocyte-stimulating hormone; bHGF,
beta chain hepatocyte growth factor; DKK, dickkop; ET, endothelin; HGF, hepatocyte growth
factor; IL, interleukin; NRG, neuregulin; PGE, prostaglandin; SCF, stem cell factors; sFRP,
secreted frizzled-related protein; VL, visible light; WIF, Wnt inhibitory factor. Reprinted from
Passeron et al29 with permission from John Wiley & Sons, Inc.

or benign pigmented lesions on acral sites, can be
challenging in people with dark pigmentation.
Furthermore, low public awareness and less access
to medical care for some populations contribute to
delays in diagnosis.43
Cutaneous squamous cell carcinoma (cSCC) is the
most commonly diagnosed skin cancer in some
populations of SOC.2 As with melanomas, cSCC in
SOC often presents in areas not exposed to sunlight,
including the lower extremities and anogenital area.2
Basal cell carcinoma is also less common in individuals with dark pigmentation but does occur and
can result in significant morbidity.44 Unlike melanomas and cSCC, basal cell carcinoma usually occurs
in sun-exposed areas of skin. In people with SOC,
both cSCC and basal cell carcinoma tend to be
pigmented. Dermatologists should be familiar with
the clinical presentations of cutaneous malignancies
in individuals with dark skin to adequately educate
patients about risks and preventative strategies.44
Many patients and physicians still incorrectly
perceive that dark pigmentation translates to complete protection from skin cancer and sun damage.44

SUN PROTECTION RECOMMENDATIONS
FOR PERSONS WITH SOC
Misconception: broad-spectrum sunscreens
provide photoprotection against all
wavelengths of light that cause skin damage
Currently available broad-spectrum sunscreens in
the United States provide 90% of their protection at
wavelengths shorter than 370 nm. The American
Academy of Dermatology recommends the use of
broad-spectrum sunscreens with SPF 30 or higher as
a cornerstone of photoprotection with a focus on UV
radiation.45 However, broad-spectrum sunscreens
are not protective against VL and UV-A1, which
contribute to diseases of hyperpigmentation, as
discussed above.3,12 Confusion persists among both
clinicians and patients regarding need for protection
against VL wavelengths.3
Misconception: sunscreen use does not result
in similar benefits in all FSTs
Many patients with SOC tell clinicians that they
believe their dark skin color means that they do not
need to use sun protection. One study showed that
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Blacks who had experienced severe sunburns were 7
times less likely to use sunscreen than Whites with a
similar experience.46 When sunscreens are used,
they are often applied insufficiently and not reapplied with adequate frequency.46
In 2020, Grimes et al11 reported that 12 months of
daily photoprotection with a sunscreen of SPF 30 and
persistent pigmentation darkening rating 20, an indicator of UV-A protection, in patients with FSTs IV
to VI improved signs of photoaging and pigmentary
concerns. A total of 24 patients used daily sunscreen,
and results were compared with 16 individuals of the
same age and phototypes who did not use sunscreen. While pigmented lesions in the control group
worsened, particularly in summer months, there
were significant clinical improvements in hyperpigmentation and dark spots in the group using photoprotection that blocked UV-A.11 In addition,
Wanitphakdeedecha et al47 reported the incidence
of PIH was significantly reduced by use of a broadspectrum sunscreen of SPF 60 or greater that
contained the anti-inflammatory agents licochalcone
A and glycyrrhetinate in FST IV treated with ablative
fractional skin resurfacing. Patients with FSTs IV to VI
should be counseled to incorporate a broadspectrum sunscreen that includes VL protection, as
part of their overall photoprotective practices, to
minimize the risk of dyspigmentation.29
Educating patients to dispel myths
Educating patients with SOC about the need for
photoprotection is imperative and targeting young
people may be particularly effective. In a study of
3710 children in 4th and 5th grade, educational
intervention increased photoprotective behaviors
by 30%.48 Different educational programs may be
needed for specific population groups. It should be
noted that adults are most prone to dyspigmentation,
so it is important to educate all ages.

DIFFERENTIATING AMONG SUNSCREEN
TYPES
Misconception: a broad-spectrum sunscreen
with SPF 30 or higher is adequate for all skin
types
The assessment of the efficacy of sunscreens in
protecting skin from harm is reflected in the SPF and,
in the United States, the critical wavelength test.49
SPF primarily indicates protection against UVinduced skin erythema (burning), which is due
primarily to UV-B.49 To be labeled broad-spectrum,
the Food and Drug Administration requires that
sunscreens have a critical wavelength of 370 nm or
above; namely, products would have to be able to
absorb 90% of the UV photons at 370 nm or above.
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Table I. Recommendations for the use of sunscreen
Daily sunscreen photoprotection is beneficial for all skin
phototypes. The type of sunscreen should be adapted
both to skin phototype and to the extent of daily sun
exposure (occupational, geographic)
Protection against UV-A wavelengths is important for all
skin types, especially for those with FST IV-VI
For FST IV-VI, broad-spectrum sunscreen with SPF of 30 or
above should be recommended
Tinted sunscreens, which contain iron oxide pigments,
protect against VL and are recommended for prevention
and treatment of pigmentary disorders in FST IV-VI
FST, Fitzpatrick skin type; SPF, sun protection factor; VL, visible
light.

No specific guidance on VL protection has been
developed by the Food and Drug Administration or
any other regulatory agency worldwide; however,
this is clearly needed in view of the now known
photobiologic effects of VL.

Strategies to target VL
As discussed by Lim et al22 in their article, Impact
of Visible Light on Skin Health: The Role of
Antioxidants and Free Radical Quenchers in Skin
Protection, elsewhere in this supplement, UV radiation greatly increases the number of ROS in the
skin.49 This oxidative stress contributes to dyspigmentation, because ROS stimulate melanogenesis
and activate a number of other pathways involved
in photodamage that lead to increased skin
pigmentation.49
As a result, sunscreens have been formulated with
antioxidants to scavenge ROS and prevent the harmful consequences of these molecules. Supplemental
antioxidants include vitamin E (a-tocopherol),
vitamin C, licochalcone A, and diethylhexyl syringylidenemalonate. As examples of the actions of these
ingredients, vitamin E both scavenges free radicals
and prevents formation of ROS during lipid oxidation.50,51 Furthermore, vitamin E is protective of fatty
acids and phospholipids in cutaneous membranes.52
Vitamin C, which is optimized when used in combination with vitamin E, also protects membranes by
limiting oxidative damage.53,54 Licochalcone A has
antioxidant properties and induces Nrf2, a master
regulator of antioxidant defenses and cellular redox
signaling. Optimally, antioxidants in sunscreens
should demonstrate excellent biologic activity
when applied, along with good photostability.49
There is a need for controlled clinical trials to
demonstrate the potential benefits of antioxidants
in sunscreen products.
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Another strategy is to reflect sunlight.55 Minor
particles (micro- or nanoscale) act through the
absorption of UV radiation, and larger particles also
act by reflecting UV or VL photons. Larger particle
sizes offer greater protection against VL, but also
deposit a whitish appearance on the skin that can be
unappealing to individuals, particularly those with
dark skin types.56 Inorganic sunscreens (non-carbonebased) containing ingredients such as zinc
oxide, iron oxide, or titanium dioxide act via absorption, reflection, and scattering of solar radiation.18 The SPF value of inorganic sunscreens is
partly related to the opacity of the product.57 Tinted
sunscreens containing iron oxides and pigmentary
titanium dioxide have been shown to be effective in
preventing and treating dyspigmentation by reflecting the long UV-A and high-energy VL ranges.58 The
addition of colored tint to inorganic sunscreens can
enhance their cosmetic acceptability, but patients
with SOC may still experience difficulty matching
their skin tone. Patients should be encouraged to
apply these products thoroughly as a way to
diminish the whitish cast and enhance the cosmetic
appearance of the products.

SUMMARY AND CONCLUSION
Disorders of dyspigmentation, such as melasma
and PIH, are common and have been associated with
a marked negative impact on quality of life and
increased disease burden among patients with FSTs
IV to VI. Photoprotection measures (Table I),
including seeking shade when outdoors, using
photoprotective clothing, and applying broadspectrum, tinted sunscreens that protect against UV
and VL may be beneficial for the prevention and
treatment of these conditions. Although the incorporation of antioxidants into formulations is a
promising new approach, there is a need for
additional research into novel strategies to address
VL damage, in addition to UV damage, in patients
with SOC.
Many individuals with dark skin may see themselves as exempt from needing sun protection and
misunderstand how sunscreens can be beneficial
for them when incorporated into overall photoprotection strategies. Furthermore, skin cancers in
patients with SOC often appear in locations
different from non-SOC patients. Educational interventions tailored specifically to the needs of
patients with SOC are lacking and are urgently
needed. It is therefore recommended that efforts on
patient education regarding sun protection and skin
cancer prevention may be best directed toward the
individual’s skin color based on FSTs or until more
objective measures are developed that may allow

clinicians to better estimate the proportion of
melanin content for each individual patient.
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